EVEREST MED.LTD DL-0001 - Asset Resilience Ratio
EVEREST MED.LTD DL-0001 (6HN) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6HN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how EVEREST MED.LTD DL-0001's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 6HN asset base.
Liquid Assets Composition Over Time
This chart breaks down EVEREST MED.LTD DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 6HN total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €517.64 Million | 6.13% |
| Total Liquid Assets | €517.64 Million | 6.13% |
Asset Resilience Insights
- Limited Liquidity: EVEREST MED.LTD DL-0001 maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EVEREST MED.LTD DL-0001 Industry Peers by Asset Resilience Ratio
Compare EVEREST MED.LTD DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for EVEREST MED.LTD DL-0001 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for EVEREST MED.LTD DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.98% | €887.09 Million ≈ $1.04 Billion |
€6.83 Billion ≈ $7.99 Billion |
-1.52pp |
| 2024-12-31 | 14.50% | €718.84 Million ≈ $840.40 Million |
€4.96 Billion ≈ $5.80 Billion |
-17.15pp |
| 2023-12-31 | 31.64% | €1.83 Billion ≈ $2.14 Billion |
€5.77 Billion ≈ $6.75 Billion |
+14.10pp |
| 2022-12-31 | 17.55% | €1.16 Billion ≈ $1.36 Billion |
€6.61 Billion ≈ $7.73 Billion |
-- |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more